ENT / Otorhinolaryngology Genetics Panel
The ENT Genetics Panel is an advanced targeted Next-Generation Sequencing (NGS) assay designed to comprehensively profile the genetic landscape of inherited and acquired otorhinolaryngological conditions. By evaluating genes governing auditory function, vestibular pathways, head and neck oncogenesis, and craniofacial development, this panel resolves diagnostic ambiguity in congenital/late-onset hearing loss, hereditary head and neck tumors, and olfactory disorders.
Key Features & Advantages
- Precise Hearing Loss Diagnosis: Deciphers genetic etiologies in pediatric and adult-onset sensorineural hearing loss, directly informing choices between conventional hearing aids and Cochlear Implantation.
- Ototoxicity Risk Prevention: Identifies mitochondrial variants (e.g., MT-RNR1) associated with aminoglycoside-induced ototoxicity to prevent irreversible drug-induced hearing loss.
- Early Syndromic Identification: Differentiates isolated hearing loss from syndromic forms (e.g., Usher, Pendred, Alport syndromes) prior to the manifestation of secondary ocular, renal, or endocrine symptoms.
- Cascade Screening & Genetic Counseling: Establishes precise inheritance models (autosomal dominant/recessive, X-linked, mitochondrial) to facilitate family planning and relative risk stratification.
ENT NGS Panel vs. Conventional Audiological / Clinical Testing
| Feature | ENT Genetics Panel (NGS) | Standard Clinical / Audiological Tests (ABR, OAE, CT) |
| Diagnostic Level | Direct genomic and molecular root cause | Functional degree of auditory or structural impairment |
| Etiological Resolution | High (Pinpoints exact causative gene & mutation) | Moderate (Confirms presence/degree of loss, not cause) |
| Syndromic Prognosis | Yes (Predicts future systemic complications like vision loss) | No (Evaluates immediate organ function only) |
| Ototoxic Sensitivity | Yes (Identifies drug-induced hearing loss risks) | No |
| Sample Requirement | Peripheral Blood, Saliva, or Tissue Sample | Non-invasive physiological and imaging measurements |
Key Applications
- Hereditary Hearing Loss & Deafness: Profiling non-syndromic (GJB2, GJB6, SLC26A4) and syndromic loci (Usher, Pendred, Waardenburg, Alport syndromes).
- Head & Neck Malignancies: Genomic characterization of Head and Neck Squamous Cell Carcinoma (HNSCC) and nasopharyngeal carcinomas.
- Hereditary Paraganglioma / Pheochromocytoma: Screening SDHx complex genes (SDHB, SDHD) for familial head and neck paragangliomas.
- Olfactory & Craniofacial Disorders: Genetic evaluation of congenital anosmia and structural craniofacial anomalies affecting ENT structures
- .
The Nucleus Genetics Advantage: Combining high-coverage NGS panels optimized for audiogenetics and head & neck oncology with specialized clinical curation by medical geneticists and ENT specialists, we deliver actionable genomic intelligence for personalized patient care.
Get Information About This Service
Our expert team is ready to answer your questions and offer tailored solutions.
Contact Form →